ProCE Banner Activity

Expert Thoughts on Key Trials of Interest for Ovarian and Cervical Cancer at the IGCS 2022 Annual Global Meeting

Podcast Episodes
In this podcast episode, listen to Susana Banerjee, MBBS, MA, PhD, FRCP, and Mansoor Raza Mirza, MD, share their thoughts on trials of interest for ovarian and cervical cancer presented at the IGCS 2022 Annual Global Meeting, including results from the highly anticipated CALLA trial, final OS analyses for ARIEL3, outcomes by previous lines of therapy from SOLO3, and results from the retrospective NeCTuR trial of topotecan, paclitaxel, and bevacizumab in neuroendocrine cervix cancer.

Released: October 24, 2022

Expiration: October 23, 2023

No longer available for credit.

Share

Faculty

Susana Banerjee

Susana Banerjee, MBBS, MA, PhD, FRCP

Consultant Medical Oncologist
Research Lead,
Gynaecology Unit
Royal Marsden NHS Foundation Trust
London, United Kingdom

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AstraZeneca

GlaxoSmithKline

Karyopharm Therapeutics Inc.

Merck Sharp & Dohme Corp.

Faculty Disclosure

Primary Author

Susana Banerjee, MBBS, MA, PhD, FRCP

Consultant Medical Oncologist
Research Lead,
Gynaecology Unit
Royal Marsden NHS Foundation Trust
London, United Kingdom

Susana Banerjee, MBBS, MA, PhD FRCP: consultant/advisor/speaker: Amgen, AstraZeneca, Clovis, Epsilogen, GlaxoSmithKline, ImmunoGen, EMD Serono, Merck Sharp & Dohme Corp, Mersana Therapeutics, Novartis, OncXerna, Pfizer, Regeneron, Roche, Seagen, Shattuck Lans, Takeda; researcher: AstraZeneca, GlaxoSmithKline.